SCHEMBL163916

SCHEMBL163916

FC(F)Oc1c[c]ccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 2/20 0.37
ALDH1A1 P00352 5/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
ALOX15 P16050 2/20 0.36
ATM Q13315 2/20 0.36
LMNA P02545 2/20 0.36
PKM P14618 2/20 0.36
HSP90AA1 P07900 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
CCR6 P51684 1/20 0.36
GFER P55789 1/20 0.36
ADAM17 P78536 1/20 0.36
MAPT P10636 4/20 0.35
RAB9A P51151 4/20 0.35
NPC1 O15118 3/20 0.35
TEAD4 Q15561 1/20 0.33
TSHR P16473 1/20 0.32
SLC6A4 P31645 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9529296 0.85
SCHEMBL5318636 0.83 MRGPRX4 (0.44) LMNAMRGPRX4
SCHEMBL17134011 0.83
SCHEMBL17134276 0.83
SCHEMBL7474148 0.80
SCHEMBL17134223 0.80
SCHEMBL17133855 0.80
SCHEMBL8800570 0.79
SCHEMBL17133997 0.79
SCHEMBL17133949 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118265702-A Microbiocidal isonicotinamide derivatives 先正达农作物保护股份公司 2024-06-28 CN claimed
WO-2024132901-A1 MICROBIOCIDAL PYRIDAZINE DIHYDROOXADIAZINE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2024-06-27 WO claimed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 US claimed
WO-2024132895-A1 MICROBIOCIDAL DIHYDROOXADIAZINYL PYRIDAZINONE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2024-06-27 WO claimed
EP-3849664-B1 PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2024-06-12 EP claimed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US claimed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 US claimed
US-11759455-B2 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2023-09-19 US claimed
EP-4217062-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 EP claimed
CN-116323557-A Cyclobutylamide monoacylglycerol lipase modulators 詹森药业有限公司 2023-06-23 CN claimed
EP-0336132-A1 1-Phenylpropyl compounds Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1989-10-11 EP claimed
WO-1989008644-A1 NEW 1-PHENYLPROPYL COMPOUNDS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1989-09-21 WO claimed
CN-1034708-A A kind of synthetic method of fluoro-Cyano chrysanthemate CHENGDU ORGANIC CHEM INST (CN) 1989-08-16 CN claimed
WO-1989003824-A1 NEW PYRROLIDINES BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1989-05-05 WO claimed
EP-0314038-A1 Pyrrolidines Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1989-05-03 EP claimed
EP-0244595-A2 Dihydropyridine derivatives, process for their preparation and their use as pharmaceutical compounds Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1987-11-11 EP claimed
US-4616002-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1986-10-07 US claimed
EP-0176956-A2 Diaryl derivatives Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1986-04-09 EP claimed
EP-0145956-A1 Composés amidés CIBA-GEIGY AG (CH) 1985-06-26 EP claimed
EP-0031104-A1 Thiazolidine compounds, processes for their preparation and pharmaceutical compositions containing them SANTEN PHARMACEUTICAL CO., LTD. (JP) 1981-07-01 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP DRD1 971/4885ALDH1A1 472/4885MEN1 3013/4885
US-11759455-B2 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators GRIN2B, GRIN2A, GRIN2C DRD1 1523/4885ALDH1A1 1382/4885MEN1 4756/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP DRD1 985/4885ALDH1A1 450/4885MEN1 2976/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP DRD1 1206/4885ALDH1A1 312/4885MEN1 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.